Join us on the latest episode! Our Guest: Michael Oleksiw, CEO at Pleio.

What you'll get out of this episode:

• Human + AI Synergy: Pleio combines emotionally aware AI with peer-to-patient support to boost medication adherence.
• Overcoming Emotional Barriers: Emotions like fear, loneliness, and stigma are major challenges after diagnosis.
• Real-World Impact: Pleio's approach improved adherence rates by up to 28% in GLP-1 medication trials.
• Ethical AI in Healthcare: Patient data is de-identified and overseen by a medical board to ensure ethical use.
• Laser Focus on Loneliness: Pleio’s next frontier is tackling loneliness as a primary emotional barrier in healthcare.

To Learn More About Our Guest And Their Company:
Guest LinkedIn https://www.linkedin.com/in/michaeloleksiw/
Company LinkedIn https://www.linkedin.com/company/pleio-inc/
Website http://www.pleio.com

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Bill Peters, CEO at On Target Laboratories.

What you'll get out of this episode:

• Innovative Imaging for Surgery – On Target Laboratories enables surgeons to see cancer at the cellular level using near-infrared imaging.
• Cytalux for Lung & Ovarian Cancer – Their FDA-approved drug, Cytalux, helps identify tumors in real-time, improving surgical outcomes.
• Surgeon-Driven Development – Continuous feedback from surgeons drives research, refining the technology for broader applications.
• Future of Cancer Surgery – With ongoing clinical trials, On Target Laboratories aims to expand its imaging technology to new indications.
• Industry Engagement – The company actively participates in key medical conferences, connecting with experts to advance cancer care.

To Learn More About Our Guest And Their Company:
Guest LinkedIn https://www.linkedin.com/in/bill-peters-749a332a/
Company LinkedIn https://www.linkedin.com/company/on-target-laboratories-inc/
Website http://www.ontargetlabs.com

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Frank Watanabe, President & CEO at Arcutis Biotherapeutics.

What you'll get out of this episode:

• Company Focus: Arcutis Biotherapeutics, under Frank Watanabe, is dedicated to treating inflammatory skin conditions, with three FDA-approved products and a fourth pending.
• Significant Milestones: This year, Arcutis launched two new products and partnered with a primary care company to expand its reach.
• Patient-Centric Approach: Arcutis prioritizes patient needs by involving dermatology practitioners and patient insights directly in decision-making.
• Technological Perspective: While acknowledging AI's potential in drug discovery, Arcutis is focused on tangible, current advancements without prematurely implementing AI.
• Expanding Accessibility: Arcutis is actively working to extend its treatments to Medicare and Medicaid markets to support a broader patient demographic.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/frank-watanabe-419711/
Company LinkedIn https://www.linkedin.com/company/arcutis-inc/
Website https://www.arcutis.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guests: Aaron Mackey, SVP of AI/Data Science at Lokavant & Jonathan Crowther, Head of Predictive Analytics at Pfizer.

What you'll get out of this episode:

• Causal AI Explained: Aaron Mackey from Lokavant and Jonathan Crowther from Pfizer discuss the capabilities of causal AI in differentiating cause and effect in clinical trials.
• Comparison to Generative AI: The episode breaks down the distinctions between generative AI and causal AI, highlighting the advantages of causal approaches in clinical operations.
• Impact on Clinical Trial Feasibility: The experts explain how causal AI optimizes trial feasibility assessments, leading to more efficient and effective clinical processes.
• Forecasting Clinical Trials with AI: Insight into how causal AI improves data-driven decision-making and addresses the limitations of traditional trial forecasts.

To learn more about our guests and their companies:
Aaron's LinkedIn https://www.linkedin.com/in/aaronmackey/
Jonathan's LinkedIn https://www.linkedin.com/in/crowtherjonathan/

Lokavant LinkedIn https://www.linkedin.com/company/lokavant/
Pfizer LinkedIn https://www.linkedin.com/company/pfizer/

Lokavant Website https://www.lokavant.com/en-us/
Pfizer Website https://www.pfizer.com/

Our sponsor for this episode is:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Joerg Ahlgrimm, CEO at SK Pharmteco.

What you'll get out of this episode:

• Joerg Ahlgrimm discusses his journey in the pharmaceutical industry and his role at SK Pharmteco.
• The strategic integration of companies under SK Pharmteco to enhance global CDMO capabilities.
• The importance of a patient-centric approach in driving company success and innovation.
• Challenges and strategies for ensuring operational efficiency and overcoming funding difficulties in biotech.
• Ahlgrimm’s advice for emerging leaders on career growth and maintaining a patient-first focus.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/joerg-ahlgrimm-315a925/
Company LinkedIn https://www.linkedin.com/company/skpharmteco/
Website https://www.skpharmteco.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Elliott Green, Co-Founder & CEO at Dandelion Health.

What you'll get out of this episode:

• Elliot Green's transition from Oscar Health to founding Dandelion Health.
• Dandelion Health's innovative approach to real-world data and clinical AI.
• The importance of longitudinal data in advancing precision medicine.
• The potential of AI to accelerate drug development and improve healthcare outcomes.
• Upcoming events where Dandelion Health will share their advancements.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/elliott-green-98433b2/
Company LinkedIn https://www.linkedin.com/company/dandelion-health-ai/
Website https://dandelionhealth.ai/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Nicole K. Paulk, CEO & Founder at Siren Biotechnology.

What you'll get out of this episode:

• Nicole Paulk's early inspiration in gene therapy during her PhD at OHSU.
• The transition from academia to entrepreneurship amid COVID-19.
• Siren Biotechnology's innovative approach with AAV immunogene therapy.
• The challenges and successes in securing funding and navigating regulatory landscapes.
• The exciting transition of Siren Biotechnology from preclinical to clinical trials.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/nicolepaulk/
Company LinkedIn https://www.linkedin.com/company/siren-biotechnology-inc/
Website https://sirenbiotechnology.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Sam Cooper, Co-Founder & CTO at Phenomic.

What you'll get out of this episode:

• Sam Cooper shares his journey from Imperial College London to founding Phenomic.
• Phenomic's innovative approach combines AI with biological research.
• The company focuses on developing drugs targeting the tumor stroma.
• Phenomic's partnership with TileDB and Boehringer Ingelheim.
• Advice for budding biotech entrepreneurs from Sam Cooper.

To Learn More About Our Guests and their Companies:
LinkedIn https://www.linkedin.com/in/sam-cooper-537814134/
Company LinkedIn https://www.linkedin.com/company/phenomic/
Website https://phenomic.ai/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/